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a b s t r a c t
Interferon- based therapy for chronic hepatitis C (CHC) is associated with thyroiditis and
thyroid dysfunction (TD). This study investigated whether TD during pegylated interferon-
(PEG-IFN) plus ribavirin treatment favors sustained viral response (SVR), and also the asso-
ciation between TD and PEG-IFN formulations. This retrospective study was performed in
CHC patients who had received PEG-IFN plus ribavirin and had been followed for six months
after treatment. Several factors were compared between patients with and without TD. 119
patients were included in the study. De novo incidence of TD was found to be 16.8%, and
16 of the 18 patients with TD achieved SVR. Although this rate was higher than patients
without TD according to univariate analysis, logistic regression analysis revealed that there
was not a signiﬁcant association between TD and SVR, whereas baseline thyroperoxidase
antibody (anti-TPO) positivity was the only signiﬁcant predictor of TD. Moreover, TD was
not associated with PEG-IFN type. Both interferon- and hepatitis C virus (HCV) contributeto TD during antiviral therapy. It seems that there is no association between thyroid toxicity
and viral clearance or type of PEG-IFN; however, anti-TPO positivity before treatment is the
strongest predictor for TD during antiviral therapy.
© 2012 Elsevier Editora Ltda. Este é um artigo Open Access sob a licença de CC BY-NC-NDIntroduction
Pegylated interferon (PEG-IFN) plus ribavirin is the current
standard of care for the treatment of chronic hepati-
tis C (CHC).1 This treatment regimen has several adverse
effects, including autoimmune disorders. Thyroid dysfunc-
tion (TD) represents the most common autoimmune disorder
observed during CHC treatment.2 The incidence of TD during
∗ Corresponding author at: Gaziosmanpasa Universitesi Tip Fakultesi, In
E-mail address: ozgurgop@yahoo.com (O. Gunal).
1413-8670 © 2012 Elsevier Editora Ltda.
http://dx.doi.org/10.1016/j.bjid.2012.05.002
Este é um artigo Open Access sob a licençainterferon- (IFN-) plus ribavirin combination therapy has
been reported to occur in 4.7% to 27.8% of patients, with a
mean incidence of 12.1%.3 This condition may be the result of
immune activation by interferon.
While the epidemiology and clinical presentation of IFN-
induced TD in CHC patients have been well characterized,feksiyon Hastaliklari ve Klinik Mikrobiyoloji, 60100 Tokat, Turkey.
the mechanisms causing this condition are still poorly under-
stood. Also, there are few studies that assess the relationship
between TD and viral kinetics or virological outcome, as well
 de CC BY-NC-ND
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s the effects of the pegylated form of IFN- on the thyroid
land.3,4 This study investigated whether TD during PEG-IFN
lus ribavirin treatment of CHC is associated with treatment
ormulations (PEG-IFN-2a or 2b) or sustained viral response
SVR), and also aimed to ﬁnd the signiﬁcant predictors for TD.
aterials and methods
atients who received treatment for CHC at the infectious dis-
ases clinic of Gaziosmanpasa university hospital in Tokat,
urkey between the years 2005 and 2010 were included in the
tudy. Eligible subjects were: CHC patients who had received
eekly injections of PEG-IFN-2a or -2b plus ribavirin orally
or 48 weeks, followed for 24 weeks after treatment, who had
ormal pretreatment TSH levels, and had been examined seri-
lly for thyroid functions as well as other required parameters
thyroid abnormalities were monitored at monthly intervals).
EG-IFN-2a was administered once a week at a daily dose
f 180g, and PEG-IFN-2b was administered once a week at
daily dose of 1.5g/kg of body weight. Ribavirin was orally
dministered daily in two divided doses (1,000mg for ≤ 75kg,
,200mg for > 75kg).
Patients with hepatitis B virus infection, HIV infection,
utoimmune hepatitis, primary biliary cirrhosis, alcoholic
iver disease, or Wilson’s disease were excluded. Patients
ere classiﬁed as responders if they achieved SVR, deﬁned as
ndetectable hepatitis C virus (HCV)-RNA at six months after
ompletion of antiviral therapy. The remaining patients were
ategorized asnon-SVR. PatientswithTDwere received appro-
riate therapy for hypo- or hyperthyroidism during the course
f antiviral therapy. HCV genotyping was performed only for
atients admitted after September 2009.
tatistical analysis
ccording to Kolmogorov-Smimov normality test, the t-test
or two independent samples was used to compare age and
nodell score between two groups. Continuous data were
xpressed asmean± standard deviation (SD). The chi-squared
est was used for comparing categorical data. Categorical data
ere expressed as count (n) and percentages (%). A multiple
Table 1 – Characteristics of CHC patients including those with a
All patients No t
na Descriptives n
Treatment response (SVR) 103 68 (66.0) 85
Knodell score 94 11.17± 4.45 75
Age (years) 119 54.32± 7.92 98
Gender (female) 119 98 (82.4) 98
Type of interferon (2a/2b) 115 44/71 96
Knodell stage (≥2) 99c 45 (45.5) 80
HCV-RNA negativity at 3rd month 102 83 (81.4) 86
Anti-TPO positivity 115 9 (7.8) 95
SVR, sustained viral response; TPO, thyroperoxidase.
a n values for different parameters compared between the groups would c
b p<0.05.
c n for Knodell stage was greater than n for Knodell score because the sco2;16(5):448–451 449
logistic regression model was implemented to determine the
risk factors independently associated with TD. p-values below
0.05 were considered statistically signiﬁcant. Statistical anal-
ysis was performed by using the Statistical Package for Social
Sciences software (SPSS Statistics 19, SPSS inc., an IBM Co. –
Somers, NY)
Ethics statement
The study protocol was approved by the institutional review
board of the Gaziosmanpasa University, Tokat, Turkey (IRB No.
12BADK021).
Results
A total of 119 CHC patients who had completed the course
of antiviral treatment in the period of 2005 to 2010 were eli-
gible for the study. Two patients discontinued treatment at
the third month due to severe side effects; two other patients
stopped therapy as they failed to drop quantitative HCV-RNA
inat least 2 log at the thirdmonth (early virological nonrespon-
der). These two patients were regarded as nonresponders, as
well as those who still had detectable HCV-RNA at the sixth
month. The remaining patients received at least six months
of therapy. The non-SVR group comprised nonresponders and
relapsers. The mean age of the 119 patients was 54.32 years,
consisting of 98 women and 21 men. 20 of the 119 patients
(16.8%) developed TD during therapy. 12 patients had hyper-
thyroidismandeighthadhypothyroidismbyabnormal thyroid
function tests, ﬁrstly determined during therapy. When the
parameters between TD patients and euthyroid patients were
compared, the univariate analysis revealed that the presence
of anti-thyroperoxidase (anti-TPO) antibodies before treat-
ment was more common in patients with TD than without TD,
andpatients in theTDgroupwere younger thanpatients in the
other group (p=0.008, p=0.01). When evaluating liver ﬁbrosis
of the two groups according to Knodell staging, the number of
patients having liver ﬁbrosis of Knodell stage >1 was com-
parable between the two groups (Table 1). Of 119 patients,
16 patients did not have the data for SVR because of early
discontinuation of therapy due to a side effect orinsufﬁcient
nd without thyroid dysfunction.
hyroid dysfunction Thyroid dysfunction p-value
Descriptives n Descriptives
52 (61.2) 18 16 (88.9) 0.048b
11.36± 4.59 18 10.56± 3.99 0.496
55.22± 7.74 20 50.25± 7.73 0.010b
78 (79.6) 20 19 (95.0) 0.120
40/56 19 4/15 0.152
38 (47.5) 19 7 (36.8) 0.560
69 (80.2) 16 14 (87.5) 0.730
4 (4.2) 20 5 (25.0) 0.008b
hange because some values were absent.
res of ﬁve patients were missing.
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Table 2 – Multiple logistic regression analysis of factors associated with TD.
 St. error of  p OR 95% CI for OR
Treatment response 1.29 0.82 0.118 3.64 0,72-18.46
Age −0.05 0.03 0.113 0.94 0,88-1.01
Gender −1.05 1.10 0.342 0.34 0,04-3.05
Type of PEG-IFN −1.11 0.74 0.133 0.32 0,08-1.40
Anti-TPO 2.09 0.88 0.018 8.09 1,42-46.06
Constant 0.64 2.02 0.752 1.89
; TPTD, thyroid dysfunction; OR, odds ratio; PEG-INF, pegylated interferon-
time elapsed after completion of therapy. Of 103 patients,
68 (66%) achieved SVR. According to the univariate analysis,
TD patients achieved SVR more frequently than euthyroid
patients (p=0.048), although there was not a signiﬁcant dif-
ference between the groups regarding HCV-RNA negativity at
third month of therapy. Analysis also showed that TD was
not associated with PEG-IFN formulations. The ﬁndings of the
univariate analysis are summarized in Table 1.
HCV genotyping was performed in only 26 patients, and all
were found to have genotype 1. Due to this ﬁnding and to the
fact that the majority of Turkish HCV patients have genotype
1, statistical analysis regarding the genotype was not included
in this study.5
Multiple logistic regression analysis was performed to
determine the independent factors related to TD among
parameters that might affect TD, including age, gender, treat-
ment response, PEG-IFN formulations, and anti-TPO, and it
was found that anti-TPO was the only risk factor for TD
(Table 2).
Discussion
PEG-IFNand ribavirin combination therapy is the current stan-
dard treatment for CHC. This treatment regimen provides a
cure rate of approximately 50%. Patients with HCV genotype
2 or 3 have a better response to treatment than genotype 1
patients.1 Other favorable factors in response to treatment
include viral load (patients with low viral load have a bet-
ter response), younger age, female gender, mild liver ﬁbrosis,
compliance, duration of treatment, early viral load reduction,
and low body mass index.6,7 However, there is controversy
in the literature regarding the relationship between TD and
SVR. In this study, TD was not associated with SVR after logis-
tic regression analysis, although SVR was more commonly
achieved in patients with TD, according to the univariate anal-
ysis. In a study published in 2002, Dalgard et al. showed that
TD induced by standard IFN- therapy had no correlation with
SVR rate.8 In a recent study byTran et al.,4 the authors reported
a positive and signiﬁcant association between thyroid disease
and viral clearance. However, in another study published in
the same year, Vezali et al.9 investigated possible prognostic
factors for TD development, including pretreatment virologi-
cal parameters and viral kinetics or virological outcome, and
concluded that TD did not appear to be linked to viral kinetics
or SVR.
Chronic HCV infection has been shown to be associated
with thyroid autoimmunity and TD.3,10 Moreover, thyroidO, thyroperoxidase.
disease may also be a side effect of IFN-based treatment.2
According to previous studies, approximately 12% of patients
(ranging from 4.7% to 27.8%) receiving IFN- and ribavirin
combination therapy will develop TD.3,9 Although many stud-
ies have focused mostly on combination therapy with IFN-
plus ribavirin, there are few data regarding the effect of PEG-
IFN. Jamil et al. reported that patients who used PEG-IFN had
higher risk of TD than those using conventional interferon
(14% vs. 7%, p = 0.038).11 However, in contrast to this ﬁnding,
Tran et al.12 found that the pegylation of IFN, in combination
with ribavirin, did not cause more thyroid diseases than the
classic IFN plus ribavirin in the hepatitis C population, as the
result of a meta-analysis. In a previous report, the authors
found that the incidence of TD in CHC patients receiving PEG-
IFN plus ribavirin therapy was 11.4%, while in the current
study the incidence was found to be a little higher, however,
both were consistent with the literature.13
The most common manifestation of IFN-induced thyroid
disease has been reported to be autoimmune thyroiditis,
predominantly Hashimoto’s thyroiditis. Other autoimmune
thyroid abnormalities include Graves’ disease or increased
serum anti-thyroid antibody concentrations without TD. Also,
recent data suggest that, in addition to its immunomodulatory
mechanism, IFN- also precipitates thyroiditis by direct thyro-
toxic effects.14–16 The main risk factor for developing thyroid
disease in the course of antiviral therapy is previous positivity
for anti-thyroid antibodies, especially in older women.3,15,17
In the present study, after univariate analysis, the mean age
of patients with TD was lower than that of patients without
TD (50 versus 55), and SVR and pretreatment anti-TPO were
more commonly found in the TD group, while TD was not
found to be associated with gender, liver histology, PEG-IFN
formulation, or HCV-RNA negativity at the third month. How-
ever, among the parameters mentioned above, only anti-TPO
positivity was found to be an independent risk factor for TD
as a result of multivariate analysis. An interesting ﬁnding of
this study was that TD showed no association with virologic
response, as well as no association to PEG-IFN formulations.
The present ﬁndings were compatible with the ﬁndings in
the study by Vezali et al.,9 where they reported that early
virologic response, SVR, and PEG-IFN formulations were not
risk factors for TD, but were linked to development of other
therapy-related autoimmunedisorders. Vezali et al. also found
that HCV genotyping was not associated with TD.A limitation of this study was that baseline HCV viral load
could not be compared between the patients with TD and
without TD because different quantitative HCV-RNA assays
were applied to patients over a period of ﬁve years. Because
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his patient population consisted of patients coming from a
ingle region of Anatolia, forming a homogenous population
n terms of HCV genotype (predominantly genotype 1), mul-
icentric studies are needed to show the association between
enotype and TD.
In conclusion, it is suggested that TD can be predicted
y pretreatment anti-TPO positivity while it seems not to be
ssociated with the PEG-IFN- formulations, early virologic
esponse, or virological outcome in treated patients. Further
rospective studies are needed to conﬁrm these ﬁndings and
o clarify the role of CHC per se in TD. Finally, CHC patients
hould be screened by thyroid function tests before and during
ntiviral therapy.
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